These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22030270)

  • 1. CYP2C19 gene variants cut-off levels for on-clopidogrel platelet aggregation.
    Wiwanitkit V
    Thromb Res; 2012 Feb; 129(2):212. PubMed ID: 22030270
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S; Kojuri J; Khalili A; Azarpira N
    Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.
    Dick RJ; Dear AE; Byron KA
    Heart Lung Circ; 2011 Oct; 20(10):657-8. PubMed ID: 21215696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Searching for the ceiling: new reflections on the disposition and metabolism of clopidogrel.
    Kleiman NS
    JACC Cardiovasc Interv; 2008 Dec; 1(6):628-30. PubMed ID: 19463376
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring.
    Bernlochner I; Mayer K; Morath T; Braun S; Schulz S; Schömig A; Koch W; Kastrati A; Sibbing D
    Platelets; 2013; 24(6):500-2. PubMed ID: 22916844
    [No Abstract]   [Full Text] [Related]  

  • 7. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A current problem for regulators. Clopidogrel and pharmacokinetics].
    Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):360-7. PubMed ID: 19572363
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
    Gladding P; White H; Voss J; Ormiston J; Stewart J; Ruygrok P; Bvaldivia B; Baak R; White C; Webster M
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1095-101. PubMed ID: 19926050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
    Bhatt DL; Paré G; Eikelboom JW; Simonsen KL; Emison ES; Fox KA; Steg PG; Montalescot G; Bhakta N; Hacke W; Flather MD; Mak KH; Cacoub P; Creager MA; Berger PB; Steinhubl SR; Murugesan G; Mehta SR; Kottke-Marchant K; Lincoff AM; Topol EJ;
    Eur Heart J; 2012 Sep; 33(17):2143-50. PubMed ID: 22450429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
    Ono T; Kaikita K; Hokimoto S; Iwashita S; Yamamoto K; Miyazaki Y; Horio E; Sato K; Tsujita K; Abe T; Deguchi M; Tayama S; Sumida H; Sugiyama S; Yamabe H; Nakamura S; Nakagawa K; Ogawa H
    Thromb Res; 2011 Dec; 128(6):e130-6. PubMed ID: 21862109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
    Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
    Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
    Jeong YH; Park Y; Kim IS
    JAMA; 2011 Jun; 305(24):2520; author reply 2521-2. PubMed ID: 21693737
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.
    Price MJ; Murray SS; Angiolillo DJ; Lillie E; Smith EN; Tisch RL; Schork NJ; Teirstein PS; Topol EJ;
    J Am Coll Cardiol; 2012 May; 59(22):1928-37. PubMed ID: 22624833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.
    Peters BJ; Harmsze AM; ten Berg JM; Maitland-van der Zee AH; Tjoeng MM; de Boer A; Deneer VH
    Pharmacogenomics; 2011 Feb; 12(2):141-4. PubMed ID: 21332306
    [No Abstract]   [Full Text] [Related]  

  • 18. The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient.
    Gurbel PA; Tantry US; Shuldiner AR
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1102-4. PubMed ID: 19926051
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
    Carlquist JF; Knight S; Horne BD; Huntinghouse JA; Rollo JS; Muhlestein JB; May H; Anderson JL
    Thromb Haemost; 2013 Apr; 109(4):744-54. PubMed ID: 23364775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Taubert D; Bouman HJ; van Werkum JW
    N Engl J Med; 2009 May; 360(21):2249-50; author reply 2251. PubMed ID: 19458375
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.